Artivion (NYSE:AORT) SVP Jean Holloway Sells 2,960 Shares of Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 2,960 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $44.62, for a total transaction of $132,075.20. Following the transaction, the senior vice president directly owned 169,169 shares of the company’s stock, valued at $7,548,320.78. This represents a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Artivion Stock Performance

Shares of AORT stock traded down $1.32 during mid-day trading on Thursday, reaching $46.31. The stock had a trading volume of 46,541 shares, compared to its average volume of 432,117. The firm has a market cap of $2.19 billion, a PE ratio of -110.35 and a beta of 1.65. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04. The firm’s 50 day simple moving average is $42.61 and its 200 day simple moving average is $35.96. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last posted its earnings results on Thursday, November 6th. The company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The business had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. The business’s revenue for the quarter was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Institutional Trading of Artivion

Several institutional investors and hedge funds have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd increased its holdings in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock worth $27,000 after acquiring an additional 519 shares during the last quarter. MCF Advisors LLC boosted its holdings in shares of Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after buying an additional 614 shares during the period. Smartleaf Asset Management LLC raised its holdings in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after acquiring an additional 538 shares during the period. State of Wyoming acquired a new stake in Artivion during the third quarter worth approximately $80,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Artivion by 447.6% during the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after acquiring an additional 4,422 shares during the period. Institutional investors own 86.37% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on AORT. JMP Securities lifted their price objective on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Needham & Company LLC upped their price target on shares of Artivion from $50.00 to $58.00 and gave the company a “buy” rating in a report on Friday, November 7th. Wall Street Zen raised shares of Artivion from a “hold” rating to a “buy” rating in a research note on Monday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artivion in a research report on Wednesday, October 8th. Finally, Citizens Jmp lifted their price objective on shares of Artivion from $47.00 to $53.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.11.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.